Bipolar Disorder (2018) |
1.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYH7B |
Bipolar Disorder or Schizophrenia |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYH7B |
Depressed Affect (Nagel 2018) |
0.85 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ARFGAP2 RERE |
Depression (Nagel 2018) |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RERE |
Intelligence (Savage-Jansen 2018) |
0.88 |
4 |
1 |
2.2 |
-0.86 |
1.4e-01 |
AMT DLEU2 MARK3 RBM6 |
Neuroticism (Nagel 2018) |
0.83 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARFGAP2 RERE |
Schizophrenia (2018) |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RERE |
Worry (Nagel 2018) |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SMG6 |
Alzheimer’s Disease (including proxy) |
1.22 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MS4A2 |
Crohns Disease (2017) |
1.28 |
4 |
1 |
2.2 |
0.31 |
6.9e-01 |
AMT MARK3 RSPO3 ZHX3 |
Irritable Bowel Disease (IBD) |
1.10 |
4 |
1 |
2.2 |
0.01 |
9.9e-01 |
AMT MARK3 WNT2B ZHX3 |
Ulcerative Colitis (UC) |
0.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZHX3 |
Reaction Time |
0.98 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARFGAP2 DNAH10 |
Verbal and Numeric Reasoning (VNR) |
0.90 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Breast Cancer |
1.71 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf97 |
Age at First Birth |
1.05 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Coronary Artery Disease (CAD) |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH10 |
Crohns Disease (2012) |
1.17 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
AMT |
HDL Cholesterol |
1.47 |
5 |
2 |
4.4 |
-0.23 |
7.2e-01 |
ARFGAP2 DNAH10 FADS2 RSPO3 SIPA1 |
LDL Cholesterol |
1.22 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FADS2 |
Lupus |
1.08 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CD44 ERI1 |
Neuroticism (2016) |
1.41 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Rheumatoid Arthritis |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 |
Schizophrenia (2014) |
1.24 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RERE SMG6 |
Triglycerides |
1.50 |
4 |
1 |
2.2 |
0.11 |
8.9e-01 |
DNAH10 FADS2 HSD17B13 RSPO3 |
Blood Eosinophil Count |
0.95 |
18 |
7 |
15.6 |
0.00 |
9.9e-01 |
AKAP11 AMT C4orf14 C6orf97 DLEU2 EBPL EML6 FADS2 GATAD1 L3MBTL2 LRRC29 MARK3 MS4A14 RERE RMND1 SAPS3 SENP7 SIPA1 |
Blood Platelet Count |
1.34 |
20 |
14 |
31.1 |
0.21 |
3.7e-01 |
ARFGAP2 C4orf14 CCDC66 DOCK9 FADS2 GATAD1 GLDN HDAC5 HSD17B13 MARK3 MS4A14 RP13-514E23.2 RSPO3 SENP7 SEPT5 SERTAD2 SMG6 TIPARP WNT2B ZHX3 |
Blood Red Count |
1.02 |
21 |
12 |
26.7 |
-0.09 |
7.0e-01 |
AMT CCDC66 DNAH10 DOCK9 EML6 ESPL1 FADS2 FTH1P20 FZD7 GATAD1 GIT1 HDAC5 LSMD1 MARK3 RPL23AP32 RSPO3 SAPS3 SERTAD2 SMG6 SPTBN1 TIPARP |
Blood White Count |
1.20 |
18 |
12 |
26.7 |
-0.23 |
3.3e-01 |
C4orf14 CYP19A1 DNAH10 EYA4 FADS2 FTH1P20 GIT1 IQGAP1 LSMD1 MS4A2 RBM6 RERE RP13-514E23.2 SMG6 SPTBN1 TIPARP TPCN2 ZHX3 |
Heel T-Score |
48.39 |
101 |
101 |
224.4 |
0.99 |
1.6e-119 |
AC004549.6 AC093110.3 ACYP2 AKAP11 AMT ARFGAP2 BARX1 BCO2 BMP4 C2orf73 C4orf14 C6orf192 C6orf97 C7orf58 CADM1 CASP9 CCDC170 CCDC66 CD109 CD44 CPED1 CRIPAK CYP19A1 DAB2 DHX58 DLEU2 DNAH10 DOCK9 EBPL ECHDC1 EML6 EPDR1 ESPL1 ESR1 EYA4 FADS2 FAM210A FAM3C FGFRL1 FHL3 FTH1P20 FZD7 GATAD1 GIT1 GLDN GREM2 HDAC5 HSD17B13 IBSP IDUA IQGAP1 JAG1 KIAA1530 KLHL17 KREMEN1 L3MBTL2 LEKR1 LIN7C LRRC29 LSMD1 MARK3 MEOX2 MMAA MS4A14 MS4A2 MYH7B PKDCC RASGRF2 RBM6 RERE RHPN2 RMND1 RP11-356J5.12 RP11-500G22.2 RP13-514E23.2 RPL23AP32 RSPO3 SAPS3 SENP7 SEPT5 SERTAD2 SIPA1 SKIV2L2 SLC30A10 SLC8A1 SMG6 SPP1 SPTBN1 SRP54 SUPT3H TIPARP TMEM8A TPCN2 TSPYL6 VNN2 WARS2 WNT2B WNT4 XKR9 ZHX3 ZNF827 |
BMI |
1.03 |
10 |
7 |
15.6 |
0.29 |
4.2e-01 |
AMT CADM1 DNAH10 GIT1 MARK3 RBM6 SAPS3 SMG6 WARS2 ZNF608 |
Height |
2.02 |
45 |
34 |
75.6 |
-0.07 |
5.9e-01 |
ARFGAP2 C2orf73 C4orf14 C7orf58 CADM1 CCDC66 CPED1 CRIPAK CYP19A1 DAB2 DLEU2 DNAH10 DOCK9 EBPL EML6 EPDR1 EYA4 FADS2 FGFRL1 FHL3 GATAD1 GIT1 HSD17B13 IBSP IQGAP1 KIAA1530 KREMEN1 LRRC29 MARK3 MYH7B RMND1 RP11-500G22.2 RP13-514E23.2 RPL23AP32 SAPS3 SIPA1 SLC8A1 SPP1 SPTBN1 SUPT3H TPCN2 WARS2 WNT2B WNT4 ZNF827 |
Waist Hip Ratio (WHR) |
3.71 |
19 |
13 |
28.9 |
0.15 |
5.3e-01 |
AMT C7orf58 CPED1 CRIPAK CYP19A1 DLEU2 DNAH10 FAM3C FGFRL1 IDUA MYH7B RSPO3 SIPA1 SLC30A10 TIPARP TMEM8A WARS2 WNT4 XKR9 |
Systolic Blood Pressure |
1.70 |
14 |
10 |
22.2 |
0.17 |
5.7e-01 |
ARFGAP2 BMP4 CASP9 ESR1 FHL3 FTH1P20 GATAD1 LSMD1 RERE RP13-514E23.2 SIPA1 SMG6 WNT2B ZNF827 |
Smoking Status |
1.02 |
4 |
2 |
4.4 |
0.10 |
9.0e-01 |
C4orf14 MARK3 RERE SMG6 |
Allergy or Eczema |
1.23 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
IQGAP1 L3MBTL2 RERE |
Cardiovascular Disease |
1.29 |
9 |
3 |
6.7 |
0.05 |
9.0e-01 |
AC093110.3 FTH1P20 GATAD1 GIT1 KREMEN1 LSMD1 MARK3 RP13-514E23.2 SIPA1 |
Hypothyroidism (self reported) |
1.16 |
4 |
2 |
4.4 |
-1.00 |
4.7e-03 |
AKAP11 FADS2 FHL3 GIT1 |
Respiratory disease |
1.28 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
C4orf14 FADS2 RERE |
Type 2 Diabetes (T2D) (2018) |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MARK3 |
Lung FEV1/FVC ratio |
1.42 |
7 |
5 |
11.1 |
-0.39 |
3.4e-01 |
BMP4 FAM3C GIT1 L3MBTL2 RERE SERTAD2 SMG6 |
Lung FVC |
1.19 |
11 |
6 |
13.3 |
-0.09 |
7.7e-01 |
BMP4 C4orf14 CD109 CYP19A1 EBPL GIT1 MYH7B SAPS3 WNT2B WNT4 ZNF827 |
Neuroticism |
0.80 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARFGAP2 RERE |
Chronotype (morning person) |
1.23 |
2 |
2 |
4.4 |
0.58 |
3.1e-01 |
CRIPAK RP11-500G22.2 |
Hair Pigment |
0.61 |
11 |
8 |
17.8 |
0.32 |
3.4e-01 |
ARFGAP2 C4orf14 CD44 FADS2 LIN7C MARK3 MYH7B SAPS3 SIPA1 SPTBN1 TPCN2 |
Tanning |
0.46 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
LEKR1 MYH7B TPCN2 |
Hand grip strength (left) |
1.53 |
4 |
1 |
2.2 |
0.33 |
3.9e-01 |
C7orf58 CRIPAK DNAH10 SAPS3 |
Number of treatments/medications taken |
1.05 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FADS2 RBM6 |
Sensitivity / hurt feelings |
0.92 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Frequency of depressed mood in last 2 weeks |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Relative age of first facial hair |
1.18 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CYP19A1 SIPA1 |
Systolic blood pressure, automated reading |
1.83 |
10 |
7 |
15.6 |
0.43 |
2.2e-01 |
ERI1 ESR1 FHL3 GATAD1 RERE RP13-514E23.2 SIPA1 SMG6 WNT2B ZNF827 |
Diabetes (mother) |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZHX3 |
Impedance of leg (right) |
1.57 |
16 |
9 |
20.0 |
-0.49 |
5.3e-02 |
CADM1 CRIPAK DHX58 ERI1 IBSP KIAA1530 L3MBTL2 MARK3 RBM6 RPL23AP32 SAPS3 SMG6 WARS2 WNT2B WNT4 ZHX3 |
Leg fat-free mass (left) |
1.87 |
19 |
12 |
26.7 |
0.19 |
3.5e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DOCK9 EBPL ERI1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Trunk fat percentage |
1.35 |
13 |
6 |
13.3 |
-0.22 |
4.6e-01 |
AC093110.3 AMT CPED1 DNAH10 EML6 GIT1 HDAC5 RBM6 RERE SPTBN1 WNT2B ZHX3 ZNF608 |
Hand grip strength (right) |
1.57 |
3 |
3 |
6.7 |
-0.54 |
1.6e-01 |
C7orf58 CRIPAK DNAH10 |
Maternal smoking around birth |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MARK3 |
Fed-up feelings |
0.93 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ARFGAP2 ERI1 |
Relative age voice broke |
0.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMT |
Taking other prescription medications |
1.31 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Age when periods started (menarche) |
1.05 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP11-500G22.2 TIPARP |
Bilateral oophorectomy (both ovaries removed) |
1.43 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
WNT4 |
Serious illness, injury or assault to yourself |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SPTBN1 |
High blood pressure |
1.50 |
9 |
3 |
6.7 |
-0.13 |
7.4e-01 |
ARFGAP2 C6orf97 ERI1 FTH1P20 KREMEN1 LSMD1 RP13-514E23.2 SIPA1 SMG6 |
Hayfever, allergic rhinitis or eczema |
1.23 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
IQGAP1 RERE |
Medication: Levothyroxine sodium |
1.03 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
AKAP11 ERI1 FADS2 |
Sitting height |
2.17 |
22 |
16 |
35.6 |
0.13 |
4.7e-01 |
ARFGAP2 CD109 CRIPAK DAB2 DLEU2 DOCK9 EBPL EPDR1 ERI1 EYA4 FHL3 GATAD1 HSD17B13 IBSP KREMEN1 LRRC29 MYH7B SAPS3 SUPT3H TIPARP TPCN2 WNT4 |
Body mass index (BMI) |
1.13 |
9 |
5 |
11.1 |
0.46 |
2.1e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 MARK3 RBM6 SMG6 ZNF608 |
Impedance of leg (left) |
1.56 |
13 |
9 |
20.0 |
-0.45 |
1.2e-01 |
CADM1 DHX58 ERI1 IBSP L3MBTL2 MARK3 RBM6 RPL23AP32 SAPS3 SMG6 WARS2 WNT2B WNT4 |
Leg predicted mass (left) |
1.86 |
19 |
12 |
26.7 |
0.19 |
3.5e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DOCK9 EBPL ERI1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Trunk fat mass |
1.35 |
9 |
5 |
11.1 |
0.10 |
7.9e-01 |
AMT DLEU2 DNAH10 HDAC5 RBM6 RERE WNT2B ZHX3 ZNF608 |
Waist circumference |
1.29 |
11 |
3 |
6.7 |
0.50 |
1.2e-01 |
AMT CADM1 CRIPAK GIT1 MARK3 RBM6 RSPO3 SIPA1 SMG6 TIPARP ZNF608 |
Number of incorrect matches in round |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
EBPL |
Past tobacco smoking |
1.01 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C4orf14 MYH7B |
Nervous feelings |
1.18 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 SMG6 |
Hearing difficulty/problems with background noise |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ARFGAP2 |
Hair/balding pattern: Pattern 2 |
1.59 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
EYA4 |
Forced vital capacity (FVC) |
1.83 |
14 |
5 |
11.1 |
-0.02 |
9.4e-01 |
ARFGAP2 BARX1 C4orf14 CRIPAK CYP19A1 DLEU2 EBPL FGFRL1 FHL3 GIT1 SAPS3 SIPA1 TPCN2 WNT4 |
Heel bone mineral density (BMD) T-score, automated (right) |
33.50 |
102 |
88 |
195.6 |
1.00 |
8.4e-158 |
AC004549.6 AC093110.3 ACYP2 AKAP11 AMT ARFGAP2 BARX1 BCO2 BMP4 C2orf73 C4orf14 C6orf192 C6orf97 C7orf58 CADM1 CASP9 CCDC170 CCDC66 CD109 CD44 CPED1 CRIPAK CYP19A1 DAB2 DHX58 DLEU2 DNAH10 DOCK9 EBPL ECHDC1 EML6 EPDR1 ERI1 ESPL1 ESR1 EYA4 FADS2 FAM210A FAM3C FGFRL1 FHL3 FTH1P20 FZD7 GATAD1 GIT1 GLDN GREM2 HDAC5 HSD17B13 IBSP IDUA IQGAP1 JAG1 KIAA1530 KLHL17 KREMEN1 L3MBTL2 LEKR1 LIN7C LRRC29 LSMD1 MARK3 MEOX2 MMAA MS4A14 MS4A2 MYH7B PKDCC RASGRF2 RBM6 RERE RHPN2 RMND1 RP11-356J5.12 RP11-500G22.2 RP13-514E23.2 RPL23AP32 RSPO3 SAPS3 SENP7 SEPT5 SERTAD2 SIPA1 SKIV2L2 SLC30A10 SLC8A1 SMG6 SPP1 SPTBN1 SRP54 SUPT3H TIPARP TMEM8A TPCN2 TSPYL6 VNN2 WARS2 WNT2B WNT4 XKR9 ZHX3 ZNF827 |
Allergy |
1.14 |
4 |
2 |
4.4 |
0.35 |
6.5e-01 |
FADS2 IQGAP1 L3MBTL2 RERE |
Diabetes (self-reported) |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Hayfever/allergic rhinitis (self-reported) |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
IQGAP1 |
Fluid intelligence score |
0.97 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Illnesses of siblings |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIT1 |
Neuroticism score |
1.01 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Weight |
1.57 |
17 |
6 |
13.3 |
0.23 |
3.0e-01 |
AMT CADM1 CRIPAK DAB2 DLEU2 EBPL ERI1 GATAD1 IBSP MYH7B RBM6 SAPS3 SMG6 TMEM8A WNT2B WNT4 ZNF608 |
Impedance of arm (right) |
1.72 |
21 |
10 |
22.2 |
-0.27 |
2.1e-01 |
AC093110.3 BARX1 C4orf14 CADM1 CRIPAK DHX58 DNAH10 ERI1 FZD7 IBSP KREMEN1 L3MBTL2 MARK3 MYH7B RBM6 SAPS3 SMG6 SPTBN1 TIPARP WARS2 WNT2B |
Arm fat percentage (right) |
1.14 |
8 |
4 |
8.9 |
0.57 |
1.4e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 HDAC5 MARK3 RBM6 |
Trunk fat-free mass |
2.23 |
22 |
19 |
42.2 |
0.20 |
2.9e-01 |
ARFGAP2 C4orf14 CCDC66 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF827 |
Hip circumference |
1.40 |
15 |
6 |
13.3 |
-0.40 |
1.2e-01 |
DLEU2 DNAH10 ERI1 EYA4 GATAD1 IBSP MYH7B RBM6 RSPO3 TMEM8A TPCN2 WARS2 WNT4 ZHX3 ZNF608 |
Alcohol intake versus 10 years previously |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SIPA1 |
Father's age at death |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Worrier / anxious feelings |
1.13 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Frequency of tiredness / lethargy in last 2 weeks |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMT |
Hair/balding pattern: Pattern 3 |
1.47 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
EYA4 ZHX3 |
Number of live births |
1.31 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS2 WNT4 |
Forced expiratory volume in 1-second (FEV1) |
1.75 |
10 |
5 |
11.1 |
-0.27 |
3.1e-01 |
BARX1 C4orf14 CRIPAK DLEU2 EBPL ERI1 FHL3 SAPS3 TPCN2 WNT4 |
Pulse rate |
1.47 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
AMT LEKR1 |
Qualifications: A levels/AS levels or equivalent |
0.98 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AMT FZD7 RBM6 |
Mouth/teeth dental problems: Dentures |
0.94 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Asthma |
1.18 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS2 RERE |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.76 |
9 |
3 |
6.7 |
-0.22 |
4.3e-01 |
BARX1 C4orf14 CRIPAK DLEU2 EBPL ERI1 FHL3 SAPS3 WNT4 |
Impedance of arm (left) |
1.60 |
23 |
7 |
15.6 |
-0.31 |
1.4e-01 |
AC093110.3 BARX1 C4orf14 CADM1 CRIPAK DHX58 DNAH10 ERI1 FZD7 IBSP KREMEN1 L3MBTL2 MARK3 MYH7B RBM6 RPL23AP32 SAPS3 SMG6 SPTBN1 SRP54 TIPARP WARS2 WNT2B |
Arm fat mass (right) |
1.18 |
10 |
3 |
6.7 |
0.50 |
1.4e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 HDAC5 MARK3 RBM6 SMG6 ZNF608 |
Trunk predicted mass |
2.22 |
22 |
19 |
42.2 |
0.20 |
3.0e-01 |
ARFGAP2 C4orf14 CCDC66 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF827 |
Standing height |
1.96 |
31 |
24 |
53.3 |
-0.01 |
9.6e-01 |
ARFGAP2 C7orf58 CCDC66 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL EPDR1 ERI1 EYA4 FADS2 FGFRL1 FHL3 GATAD1 GIT1 HSD17B13 IBSP IQGAP1 KIAA1530 MARK3 MYH7B RP13-514E23.2 SAPS3 SIPA1 SUPT3H TPCN2 WNT2B WNT4 ZNF827 |
Tense / 'highly strung' |
1.43 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 RERE |
Hair/balding pattern: Pattern 4 |
1.65 |
7 |
3 |
6.7 |
-0.07 |
8.9e-01 |
FADS2 IQGAP1 LRRC29 MYH7B SMG6 WARS2 ZHX3 |
Birth weight of first child |
1.34 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
TIPARP WNT4 |
Peak expiratory flow (PEF) |
1.50 |
4 |
2 |
4.4 |
-0.41 |
5.0e-01 |
BMP4 DLEU2 ERI1 SAPS3 |
Gout (self-reported) |
1.07 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
IBSP SIPA1 |
Hypothyroidism/myxoedema (self-reported) |
1.12 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
AKAP11 ERI1 FADS2 |
Medication: Amlodipine |
1.45 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SIPA1 |
Birth weight |
1.85 |
5 |
2 |
4.4 |
0.44 |
4.5e-01 |
KREMEN1 RSPO3 SMG6 TIPARP WNT4 |
High blood pressure (siblings) |
1.40 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIT1 SMG6 |
Forced vital capacity (FVC), Best measure |
1.84 |
12 |
5 |
11.1 |
-0.08 |
7.5e-01 |
ARFGAP2 BARX1 C4orf14 CRIPAK CYP19A1 DAB2 DLEU2 EBPL FHL3 GIT1 SAPS3 WNT4 |
Body fat percentage |
1.31 |
12 |
6 |
13.3 |
-0.06 |
8.6e-01 |
AC093110.3 AMT DNAH10 GIT1 HDAC5 MARK3 RBM6 RERE SPTBN1 WNT2B ZHX3 ZNF608 |
Leg fat percentage (right) |
1.25 |
9 |
6 |
13.3 |
0.00 |
9.9e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 RBM6 RERE WNT2B ZHX3 |
Arm fat-free mass (right) |
2.09 |
21 |
14 |
31.1 |
0.34 |
6.9e-02 |
C4orf14 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SIPA1 SMG6 SUPT3H ZNF608 |
Comparative body size at age 10 |
1.24 |
5 |
2 |
4.4 |
0.72 |
1.7e-01 |
ERI1 L3MBTL2 SAPS3 SMG6 WNT2B |
Worry too long after embarrassment |
0.91 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Wheeze or whistling in the chest in last year |
1.10 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 RERE |
Age at first live birth |
0.86 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Qualifications: College or University degree |
0.76 |
4 |
2 |
4.4 |
-0.10 |
9.0e-01 |
AMT MYH7B RBM6 RERE |
Medication: Blood pressure |
1.19 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 SIPA1 |
Medication: Ibuprofen |
1.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FTH1P20 |
Medication: Allopurinol |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LSMD1 |
Mean time to correctly identify matches |
1.00 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ARFGAP2 |
Whole body fat mass |
1.29 |
10 |
5 |
11.1 |
0.13 |
7.3e-01 |
AMT DNAH10 GIT1 HDAC5 MARK3 RBM6 RERE WNT2B ZHX3 ZNF608 |
Leg fat mass (right) |
1.28 |
10 |
3 |
6.7 |
-0.02 |
9.5e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 RBM6 RERE WNT2B ZHX3 ZNF608 |
Arm predicted mass (right) |
2.09 |
20 |
13 |
28.9 |
0.26 |
1.9e-01 |
CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Pulse rate, automated reading |
1.69 |
9 |
5 |
11.1 |
0.18 |
6.3e-01 |
AMT CCDC66 CRIPAK FADS2 LEKR1 MYH7B RBM6 SERTAD2 ZHX3 |
Alcohol intake frequency. |
0.79 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AMT RBM6 |
Comparative height size at age 10 |
1.47 |
15 |
8 |
17.8 |
-0.05 |
8.4e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DNAH10 EBPL GATAD1 IQGAP1 KIAA1530 MARK3 SAPS3 SUPT3H WARS2 WNT2B WNT4 |
Suffer from 'nerves' |
1.21 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 SMG6 |
Overall health rating |
0.91 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF608 |
Chest pain or discomfort |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SIPA1 |
Age at last live birth |
1.10 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBM6 |
Qualifications: NVQ or HND or HNC or equivalent |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Medication: Aspirin |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FTH1P20 |
Hypertension (Self-reported) |
1.48 |
8 |
3 |
6.7 |
0.02 |
9.6e-01 |
ARFGAP2 ERI1 FTH1P20 KREMEN1 LSMD1 RP13-514E23.2 SIPA1 SMG6 |
Illnesses of father: Heart disease |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH10 |
Forced expiratory volume in 1-second (FEV1), predicted |
1.62 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DLEU2 EPDR1 |
Whole body fat-free mass |
2.10 |
23 |
16 |
35.6 |
0.22 |
2.4e-01 |
ARFGAP2 C4orf14 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 ZNF827 |
Leg fat-free mass (right) |
1.87 |
19 |
13 |
28.9 |
0.20 |
3.2e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DOCK9 EBPL ERI1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Arm fat percentage (left) |
1.21 |
9 |
4 |
8.9 |
0.48 |
1.9e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 HDAC5 MARK3 RBM6 RERE |
Mood swings |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Diabetes diagnosed by doctor |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Breast cancer (self-reported) |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf97 |
Asthma (self-reported) |
1.15 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
FADS2 RERE |
Osteoporosis (self-reported) |
4.00 |
7 |
4 |
8.9 |
-0.64 |
1.2e-01 |
CPED1 DNAH10 ESPL1 GREM2 LIN7C SAPS3 SPP1 |
Medication: Aspirin |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FTH1P20 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
WNT4 |
Whole body water mass |
2.11 |
23 |
16 |
35.6 |
0.22 |
2.4e-01 |
ARFGAP2 C4orf14 CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 ZNF827 |
Leg predicted mass (right) |
1.86 |
19 |
13 |
28.9 |
0.20 |
3.3e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DOCK9 EBPL ERI1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Arm fat mass (left) |
1.21 |
9 |
3 |
6.7 |
0.44 |
2.4e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 HDAC5 MARK3 RBM6 ZNF608 |
Number of self-reported non-cancer illnesses |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LSMD1 |
Miserableness |
1.08 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ARFGAP2 ERI1 |
Guilty feelings |
1.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Medication: Blood pressure |
1.57 |
4 |
2 |
4.4 |
0.69 |
3.1e-01 |
ERI1 LSMD1 SIPA1 WNT2B |
High cholesterol (Self-reported) |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MS4A14 |
Medication: Bendroflumethiazide |
1.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Illnesses of father: High blood pressure |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RP13-514E23.2 |
Ever smoked |
0.84 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
C4orf14 |
Basal metabolic rate |
1.98 |
21 |
15 |
33.3 |
0.27 |
1.6e-01 |
ARFGAP2 CRIPAK DAB2 DLEU2 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 ZNF827 |
Leg fat percentage (left) |
1.23 |
10 |
5 |
11.1 |
0.12 |
7.5e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 MARK3 RBM6 RERE WNT2B ZHX3 |
Arm fat-free mass (left) |
2.04 |
20 |
12 |
26.7 |
0.25 |
2.1e-01 |
CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H WNT4 ZNF608 |
Average weekly beer plus cider intake |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ERI1 |
Irritability |
1.18 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ERI1 |
Fractured/broken bones in last 5 years |
5.49 |
9 |
4 |
8.9 |
-0.97 |
3.4e-11 |
C6orf97 C7orf58 CPED1 CRIPAK FAM3C FGFRL1 HDAC5 RSPO3 TPCN2 |
Diastolic blood pressure, automated reading |
1.62 |
11 |
5 |
11.1 |
0.21 |
5.4e-01 |
AMT EML6 ERI1 LSMD1 RERE RP13-514E23.2 SIPA1 SMG6 SPTBN1 WNT2B ZHX3 |
Myopia |
1.19 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
BMP4 FADS2 |
Vascular/heart problems diagnosed by doctor |
1.50 |
8 |
4 |
8.9 |
0.09 |
8.4e-01 |
ARFGAP2 ERI1 FTH1P20 GIT1 KREMEN1 LSMD1 SIPA1 SMG6 |
Cholesterol lowering medication |
1.37 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DNAH10 GIT1 |
Pain experienced in last month |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ECHDC1 |
Basal cell carcinoma (self-reported) |
1.30 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SAPS3 |
Impedance of whole body |
1.64 |
19 |
10 |
22.2 |
-0.41 |
8.4e-02 |
AC093110.3 C4orf14 CADM1 CRIPAK DHX58 DNAH10 ERI1 FZD7 IBSP KIAA1530 L3MBTL2 MARK3 MYH7B RBM6 RPL23AP32 SAPS3 SMG6 WARS2 WNT2B |
Leg fat mass (left) |
1.30 |
11 |
3 |
6.7 |
0.08 |
8.2e-01 |
AMT CADM1 DNAH10 ERI1 GIT1 MARK3 RBM6 RERE WNT2B ZHX3 ZNF608 |
Arm predicted mass (left) |
2.04 |
20 |
13 |
28.9 |
0.25 |
2.1e-01 |
CRIPAK DAB2 DLEU2 DNAH10 DOCK9 EBPL ERI1 FGFRL1 FHL3 GATAD1 IBSP KIAA1530 MYH7B RBM6 RP13-514E23.2 SAPS3 SMG6 SUPT3H ZNF608 ZNF827 |